Roivant Sciences LTD. balance sheet
At the end of its fiscal year on Mar 31, 2026, Roivant Sciences LTD. reported total assets of $5.71B and shareholders' equity of $4.53B. That works out to liabilities equal to 7% of assets, a current ratio of 18.37 (current assets ÷ current liabilities).
Balance sheet at each fiscal year end
| Fiscal year ended | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Total assets | $2.59B | $2.59B | $2.39B | $7.22B | $5.44B | $5.71B |
| Current assets | $2.19B | $2.15B | $1.80B | $6.73B | $5.00B | $5.17B |
| Cash & equivalents | $2.06B | $2.06B | $1.68B | $6.49B | $2.72B | $1.42B |
| Total liabilities | $527.69M | $523.70M | $782.02M | $773.95M | $249.74M | $416.27M |
| Current liabilities | $218.96M | $184.37M | $272.45M | $266.76M | $149.41M | $281.24M |
| Long-term debt | $170.28M | $210.03M | $375.51M | $430.59M | — | — |
| Shareholders' equity | $1.80B | $1.66B | $1.16B | $5.97B | $4.69B | $4.53B |
| Reported in | 10-K 2022 | 10-K 2023 | 10-K 2024 | 10-K 2025 | 10-K 2026 | 10-K 2026 |
Balance-sheet figures are point-in-time values on the last day of each fiscal year. Some companies (for example banks and insurers) do not present current assets and liabilities; those cells show —.
Source: SEC EDGAR XBRL company facts for CIK 1635088 (raw data). Most recent filing in this dataset: 10-Q filed Aug 6, 2026. SEC data file dated Nov 3, 2026; page built Nov 5, 2026. Figures are as most recently reported, including restatements. How we select figures.